Abstract 1224: Insights into the mechanism of action of NVP-HDM201, a differentiated and versatile Next-Generation small-molecule inhibitor of Mdm2, under evaluation in phase I clinical trials

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer Research

• Publication date

  2016-07-15

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/1538-7445.AM2016-1224
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• p53 biology and reactivation for improved therapy in MDS and AML

  2024cites this paper
• miR-16-5p enhances sensitivity to RG7388 through targeting PPM1D expression (WIP1) in Childhood Acute Lymphoblastic Leukemia

  2023cites this paper
• MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation

  2023cites this paper
• Small-molecule MDM2 inhibitors in clinical trials for cancer therapy.

  2022cites this paper
• Role of Sex in the Therapeutic Targeting of p53 Circuitry

  2021cites this paper
• Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors

  2021cites this paper
• MDM2 inhibition: an important step forward in cancer therapy

  2020cites this paper
• Targeting p53-MDM2 interaction using small molecule inhibitors and the challenges needed to be addressed.

  2019cites this paper
• MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer

  2017cites this paper